This article is part of a special supplement published by Nephrology News & Issues in the February 2014 issue entitled, "Iron therapy and a quarter century of ESAs: What have we learned?" The ...

Washington, DC - Intravenous iron sucrose therapy as an adjuvant treatment to erythropoiesis-stimulating agents (ESA) can help effectively battle anemia in peritoneal-dialysis (PD) patients and avoid ...

Vascular Calcification mortality non-dialysis CKD Study shows benefit of initiating epoetin beta therapy at hemoglobin levels not less than 10 g/dL in non-dialysis CKD patients. Earlier treatment of ...

Company Recommends Hemoglobin Target of 10-12 g/dL as Risk Management Approach THOUSAND OAKS, Calif. -- Sept. 11, 2007--Amgen is presenting data today on the appropriate use of Erythropoiesis ...

Please provide your email address to receive an email when new articles are posted on . We learned from the nephrologists that even in what we consider iron-replete patients who are receiving ESAs, ...

statin-therapy_1115 Using statins for more than 3 months was significantly associated with 85% lower odds of ESA hyporesponsiveness in CKD patients. Statin therapy may curb hyporesponsiveness to ...